Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of Therapeutic Layering of Stereotactic Body Radiotherapy on Darolutamide in the Management of Oligoprogressive Castration Resistant Prostate Cancer: A Pilot Phase II Trial

NCT04070209 is registered in ClinicalTrials.gov with Sir Mortimer B. Davis - Jewish General Hospital as lead sponsor.

NCT NCT04070209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04070209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of Therapeutic Layering of Stereotactic Body Radiotherapy on Darolutamide in the Management of Oligoprogressive Castration Resistant Prostate Cancer: A Pilot Phase II Trial
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 19, 2020
Completion date
November 30, 2030
Enrollment
66 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, metastatic prostate cancer